fauxcroft

You helped pay for it twice, and you may not have even realized it. First, your tax dollars funded the groundbreaking research in government labs and universities that led to the life-saving drug, and then you are asked to pay an exorbitant price at the pharmacy counter just to stay alive. This is the hidden reality of the American pharmaceutical industry, where companies take publicly funded discoveries, patent them, and mark up the price by thousands of percent with little justification. In this post, we will pull back the curtain on how Big Pharma turns your investment into their fortune, why Americans pay more for medications than anyone else in the world, and what can be done to fix a broken system that puts profits over patients.

1. The Double Payment Dilemma: How Taxpayers Fund Drug Development Twice

Imagine paying for a meal twice — once to buy the ingredients and again to eat it. That is exactly what is happening with prescription drugs in America.

Most people assume that pharmaceutical companies fund their own research from scratch, taking on all the risk to develop life-saving medications. The reality is far different. A staggering amount of foundational drug research is funded by you, the taxpayer. Through federal agencies like the National Institutes of Health, or NIH, the government pours tens of billions of dollars every year into basic scientific research at universities and labs across the country. This is the crucial, high-risk early-stage science that identifies how a disease works and which biological targets might treat it.

Pharmaceutical companies then step in, often licensing these taxpayer-funded discoveries for a fraction of their true value. They handle the later stages of development, like clinical trials, and then patent the final product. Once that patent is secured, they gain a monopoly and set the price at whatever the market will bear — even though the public already paid for the groundwork.

The result is the double payment dilemma. You pay first through your taxes to make the drug possible, and you pay a second time at the pharmacy counter, often at an astronomical markup. Studies have shown that every single one of the 210 new drugs approved in the United States between 2010 and 2016 was rooted in NIH-funded research. Yet Americans pay two to three times more for those same drugs than patients in other developed countries. We are not just customers; we are unwitting investors who never see a return, only a bill.

2. From Lab to Market: How NIH and Public Grants Fuel Pharmaceutical Breakthroughs

Behind every blockbuster drug with a five-figure price tag is a long trail of publicly funded science that most patients never see. The journey rarely starts in a corporate lab. It starts in university research buildings and federal laboratories, where scientists funded by the National Institutes of Health, the National Science Foundation, and other public grants do the high-risk, foundational work of understanding diseases at a molecular level.

This early-stage research is where the real breakthroughs happen — identifying a viral protein, mapping a genetic mutation, or discovering a new biological pathway. It is slow, expensive, and often fails, which is exactly why private companies tend to avoid it. Taxpayers, however, have bankrolled it for decades. The NIH alone invests more than $40 billion annually in biomedical research, and studies have found that every single new drug approved by the FDA between 2010 and 2019 was linked to NIH-funded science.

Only after that groundwork is laid, after a promising compound or mechanism has been de-risked with public money, does the pharmaceutical industry typically step in. Companies license the discovery, run the later-stage clinical trials, and bring the drug to market — then set a price as if they had borne the entire cost of innovation alone. That is how the public ends up paying twice: first to help create the drug, and again at the pharmacy counter to afford it.

3. The Patent Playbook: How Evergreening and Patent Thickets Keep Prices High

When a pharmaceutical company develops a new drug, it is granted a patent that typically lasts 20 years from the filing date, giving the company exclusive rights to sell the drug without competition. In theory, once that patent expires, other manufacturers can produce generic versions, which drives the price down dramatically. In practice, brand-name manufacturers have developed sophisticated legal strategies to extend that period of exclusivity far beyond the original 20 years.

One of the most common strategies is known as evergreening. This involves making minor modifications to an existing drug and filing a new patent on the modification, rather than the underlying active ingredient. The change might be a new formulation, such as switching from a tablet to an extended-release capsule, a new dosage, a new method of delivery like an inhaler, or even a change in the inactive coating. While these tweaks can sometimes offer a real benefit to patients, they often provide little therapeutic advantage and are primarily used to secure a new patent and reset the clock on exclusivity.

Closely related is the practice of building patent thickets. Instead of filing a single patent on a drug, a company may file dozens or even hundreds of separate patents covering every aspect of the product — the molecule itself, the manufacturing process, the chemical formulation, the device used to administer it, and the specific way it is prescribed. A well-known example is Humira, the arthritis drug, which was protected by more than 100 patents in the United States. For a generic competitor to enter the market, it must challenge or work around each patent individually in court, a process that can take years and cost millions of dollars in legal fees.

Together, these tactics create a legal maze that delays generic competition. Even when a generic company successfully invalidates several patents, a single remaining patent can be enough to keep it off the market. During this extended monopoly period, the brand-name company can continue to set prices without competitive pressure, which is a major reason why drug prices in the United States remain high long after the initial research and development costs have been recovered.

4. Paying to Play: The Role of Lobbying and Political Influence in Drug Pricing

The pharmaceutical industry is one of the most powerful lobbying forces in Washington, outspending almost every other sector year after year. In 2023 alone, Big Pharma spent over $375 million on lobbying efforts, employing roughly three lobbyists for every single member of Congress. That money isn’t just for access, it’s for influence, and it pays off.

This influence is a key reason why drug prices in the United States remain astronomically higher than in any other developed nation. For decades, pharma lobbyists have successfully blocked legislation that would allow Medicare — the largest single purchaser of prescription drugs in the country — to negotiate prices directly with drug companies. While every other major government health system in the world negotiates bulk discounts, the U.S. was legally prohibited from doing so until the very limited reforms of the Inflation Reduction Act of 2022, a bill that was dramatically watered down from its original form after intense industry opposition.

Lobbying also protects lucrative patent games. Pharmaceutical companies spend millions to influence patent law and FDA regulations, allowing them to engage in practices like patent evergreening and pay-for-delay deals, where brand-name manufacturers pay generic competitors to keep cheaper alternatives off the market. These tactics extend monopolies for years, even decades, keeping prices artificially high long after the initial research costs have been recouped.

And the cycle doesn’t stop in Washington. The industry pours tens of millions into campaign contributions, funding candidates on both sides of the aisle who can be counted on to vote against price caps, importation of cheaper drugs from Canada, and transparency bills. It also funds patient advocacy groups and front organizations that appear to represent consumers but quietly advocate for industry-friendly policies.

The result is a political system where the people who are supposed to regulate drug prices are heavily financed by the companies that profit from them. Taxpayers fund the initial research through the National Institutes of Health, patients pay exorbitant prices at the pharmacy counter, and a portion of those profits is then funneled back into the political system to ensure the prices never come down.

5. Insulin, Epipens, and Beyond: Real-World Examples of Price Gouging

Nothing illustrates the predatory pricing of the pharmaceutical industry more clearly than the stories of everyday drugs that millions of Americans depend on to stay alive.

Take insulin. Discovered over a century ago, its original patent was sold for just $1 so that it would be available to everyone who needed it. Today, the three companies that control nearly the entire U.S. insulin market — Eli Lilly, Novo Nordisk, and Sanofi — have raised the list price of the drug by over 600% in the last two decades. The drug itself hasn’t fundamentally changed, but the price has. A vial that costs less than $10 to manufacture can retail for more than $300. For diabetics who need it daily to survive, there is no choice but to pay, ration doses, or risk death. And many do ration — studies estimate one in four insulin users has skipped or reduced doses due to cost.

The EpiPen tells a similar story. Mylan acquired the rights to the epinephrine auto-injector, a device that has existed since the 1980s and delivers a generic drug that costs about a dollar per dose. Through incremental tweaks to the injector design that extended its patent protection and aggressive lobbying to get EpiPens mandated in schools, Mylan raised the price from around $100 for a two-pack in 2007 to over $600 in 2016. The CEO received a 671% pay raise during the same period. Families with severe allergies, who must replace their EpiPens every year whether they use them or not, were left scrambling to afford what is essentially a life-or-death necessity.

And the list goes on. Daraprim, a 70-year-old drug used to treat toxoplasmosis, went from $13.50 to $750 per pill overnight after Turing Pharmaceuticals acquired it. Naloxone, the opioid overdose reversal drug, has seen its price double or triple even as the opioid crisis has made it more urgently needed than ever. Even newer, taxpayer-funded breakthroughs like Sovaldi, a hepatitis C cure developed with significant NIH support, launched at $84,000 for a 12-week course.

In each case, the pattern is the same: a long-existing or publicly funded drug is acquired, its monopoly is protected not by real innovation but by patent games and market manipulation, and the price is jacked up because patients have no alternative. It is not about recouping research costs. It is about extracting maximum profit from desperation.

6. Why America Pays More: Comparing U.S. Drug Prices to the Rest of the World

If you live in the United States, you are paying more for prescription drugs than almost anyone else on earth, and it is not even close. The exact same medication, made in the same factory by the same company, can cost two to four times more at an American pharmacy than it does in Canada, the United Kingdom, Germany, or France. A RAND Corporation study found that on average, U.S. prices for brand-name drugs are more than 300% higher than prices in other developed nations. For some drugs the gap is even more extreme. Humira, the blockbuster arthritis drug, costs around $2,500 for a month’s supply in the U.S. while patients in the UK pay a fraction of that for the identical dose.

This is not because drugs are cheaper to make elsewhere. It is because other countries negotiate. In the UK, Canada, Australia and most of Europe, the government sits down with pharmaceutical companies and haggles over the price, refusing to pay more than a drug is actually worth. If a company demands too much, the government can simply say no. In the United States, that does not happen. For decades, federal law actually prohibited Medicare — the largest single buyer of prescription drugs in the world — from negotiating prices directly with drugmakers. Instead, America lets Pharma set whatever price it wants, and insurers, hospitals, and patients are left to pay it.

The result is that American patients and taxpayers are subsidizing cheap drugs for the rest of the world. Pharmaceutical companies often argue that high U.S. prices fund innovation and research, but the reality is that you have already paid for much of that research. Taxpayer money through the National Institutes of Health funds the foundational science behind nearly every major drug approved in the last decade, from cancer therapies to COVID vaccines. You pay to develop the drug, and then you pay again — at the highest price in the world — to actually use it.

7. The Myth of Innovation: Do High Prices Really Fund Future Cures?

One of the most persistent defenses offered by the pharmaceutical industry for sky-high drug prices is that they are necessary to fund innovation. Without massive profits, the argument goes, there would be no money for the risky, expensive research and development that leads to the next generation of life-saving cures. It is a compelling narrative, but the numbers tell a very different story.

First, a significant portion of foundational drug research is not funded by Big Pharma at all, but by you, the taxpayer. Through the National Institutes of Health, the federal government invests over 40 billion dollars annually in biomedical research. Studies have shown that every single one of the 210 new drugs approved in the United States between 2010 and 2016 was rooted in NIH-funded research. In effect, the public pays twice: once to fund the initial discovery in university labs, and again at the pharmacy counter when that discovery is privatized and sold back at an exorbitant markup.

Second, when you examine how pharmaceutical companies actually spend their revenue, R&D is far from the top priority. For many of the largest drug companies, more money is spent on marketing, advertising, and stock buybacks than on developing new drugs. In 2022, the 14 largest pharmaceutical companies spent over 80 billion dollars on share buybacks and dividends to enrich shareholders and executives — billions more than they spent on research. Marketing budgets, which include direct-to-consumer television ads, sales reps, and payments to doctors, routinely outpace R&D spending as well.

Finally, much of what the industry calls innovation is not innovation at all. Instead of developing truly novel medicines, companies often focus on minor tweaks to existing blockbuster drugs to extend their patents, a practice known as evergreening. Changing a pill to an extended-release capsule or combining two old drugs into one new pill can secure another decade of monopoly pricing without offering any meaningful therapeutic benefit to patients.

High prices do not guarantee future cures. They guarantee future profits.

8. Pharmacy Benefit Managers and the Hidden Middlemen Inflating Costs

If you think the price you pay at the pharmacy is set by the drug manufacturer alone, you are missing the most profitable players in the entire system. Between the pharmaceutical company that makes the drug and the pharmacy that hands it to you sits a shadowy middleman: the Pharmacy Benefit Manager, or PBM.

Originally, PBMs were supposed to save you money. Hired by insurance companies and employers to negotiate lower drug prices, they were meant to use their massive buying power to squeeze discounts out of Big Pharma. Today, three PBMs — CVS Caremark, Express Scripts, and OptumRx — control nearly 80% of all prescriptions in the United States. And instead of lowering costs, they have perfected a system for inflating them.

Here is how the game works. A drug company sets a high list price for a medication, say $500 a month. The PBM then steps in and demands a hefty rebate — perhaps $200 — in exchange for placing that drug on its formulary, which is the list of drugs your insurance will actually cover. The drug company happily pays it, because without formulary placement, no one will buy their drug.

But that $200 rebate rarely makes it back to you, the patient. The PBM pockets a significant portion as profit, claiming it as a fee for negotiating. Your insurance company gets a cut. What you are left with is a co-pay or deductible that is often calculated from the original, inflated $500 list price, not the $300 net price after the rebate. You are paying more out of pocket so the middleman can profit from a discount you never see.

This creates a perverse incentive that drives prices even higher. PBMs actually prefer drugs with higher list prices because it means larger rebates and bigger profits for them. A cheaper drug with a low list price offers no room for a lucrative rebate, so it may be excluded from the formulary entirely, even if it is just as effective and far more affordable. Manufacturers know this, so they keep raising list prices to offer bigger rebates and stay competitive for formulary placement.

It is a hidden kickback system that you already paid for twice. Your tax dollars funded the initial NIH research that led to the drug, and now your premiums and out-of-pocket costs are funding the middlemen who artificially inflate its price on the way to the pharmacy counter. Until PBMs are forced to pass rebates directly to patients and operate with transparency, the list price will remain a fiction designed to enrich everyone except the person who needs the medication to live.

9. Who Really Profits? Following the Money from Prescription to Profit

When you pick up a prescription at the pharmacy counter, the price you see is only the final step in a long and complex chain of transactions, and very little of that money stays with the pharmacist who handed you the bag.

It starts with the manufacturer who sets the list price, often called the wholesale acquisition cost. This is the starting price before any discounts or negotiations. From there, pharmacy benefit managers, or PBMs, step in. These middlemen negotiate on behalf of insurance companies and employers to get rebates and discounts from the drug maker in exchange for placing the drug on a preferred tier of the insurance formulary. The larger the rebate, the more likely the drug is to be covered.

The manufacturer pays that rebate to the PBM, the PBM passes a portion of it to the insurer, and the insurer decides how much of the savings, if any, reaches the patient. In many cases, the patient’s copay is still calculated based on the original, higher list price, not the discounted price the insurer actually paid.

Meanwhile, pharmacies buy drugs from wholesalers and are reimbursed by the PBM at a contracted rate. If that reimbursement is lower than what the pharmacy paid to stock the drug, the pharmacy loses money on the transaction. If it is higher, the pharmacy keeps the spread.

At the top of this chain, the pharmaceutical company retains the majority of the net revenue after rebates. That profit is then divided among shareholders through dividends and stock buybacks, executive compensation packages, and funding for marketing and future research and development. While companies often point to R&D costs to justify high prices, financial reports consistently show that spending on marketing, administration, and shareholder returns often exceeds direct research spending.

The result is a system where the patient pays the most while understanding the least about where their money actually goes, and where every intermediary takes a cut before the medicine ever reaches the person who needs it.

10. The Human Cost: When Patients Ration, Skip, or Go Without Medication

Behind every pricing debate and patent extension are real people forced to make impossible choices about their own health. When a life-saving medication costs hundreds or even thousands of dollars a month, many patients do not simply complain about the price — they change how they take their medication to make it last longer. They split pills in half, skip doses, stretch a 30-day supply to 45 or 60 days, or abandon prescriptions at the pharmacy counter altogether when they learn what they owe.

For people with chronic conditions like diabetes, asthma, or heart disease, this kind of rationing is not just risky, it is dangerous. Insulin is one of the most stark examples. Patients who cannot afford their full dose have ended up in emergency rooms with diabetic ketoacidosis, a life-threatening condition that is entirely preventable with consistent access to the drug. Others with asthma rely on rescue inhalers they cannot afford to replace, or with high blood pressure who stop taking daily medication because the co-pay competes with rent and groceries.

The consequences extend beyond individual health. Families go into debt, launch fundraisers, or cut back on essentials to cover a single prescription. Some turn to less effective alternatives, black-market sources, or foreign pharmacies of uncertain safety. Others simply go without treatment and hope for the best, until a preventable complication forces them into the hospital — where the cost of care far exceeds the price of the drug they could not afford in the first place.

This is the human cost that rarely appears in earnings reports. It is measured not in profit margins, but in missed workdays, hospitalizations, declining health, and lives lost to conditions that modern medicine knows how to treat, but that the current pricing system puts out of reach.

11. Failed Fixes and False Promises: Why Previous Reforms Haven’t Worked

Over the years, Washington has offered a steady stream of solutions that promised to lower drug prices but ultimately left the core problem untouched. Price transparency laws were supposed to shame companies into lowering costs, yet disclosing a list price does nothing when patients still pay whatever the pharmacy demands. Allowing the importation of cheaper drugs from Canada made for good headlines, but it was a narrow workaround that never addressed why American prices were inflated in the first place. Even the much-touted $35 insulin cap, while a genuine relief for seniors on Medicare, left millions of younger diabetics and people with other chronic conditions facing the same sky-high bills.

The reason these fixes fail is simple: they tinker around the edges of a system designed to maximize profit at every step. Reforms have focused on rebates, coupons, and negotiations with middlemen like pharmacy benefit managers, without confronting the monopoly power that lets drug companies set any price they want. Legislation is often watered down before it even passes, riddled with loopholes and concessions carved out by one of the most powerful lobbies in the country. The result is a cycle of false promises where a new bill is celebrated as a breakthrough, only for patients to find at the counter that nothing has really changed, and the price of staying alive keeps climbing.

12. What Real Reform Could Look Like: From Price Negotiation to Patent Reform

Real reform would start by fixing the two systems that let drug companies charge so much for so long: how prices are set, and how patents are used to block competition.

The first is price negotiation. For years, the largest buyer of prescription drugs in the country — Medicare — was legally barred from negotiating prices directly with manufacturers. That meant drug companies could set almost any price and the government had to pay it, even though taxpayer money had often funded the early research behind the drug through the National Institutes of Health. Allowing Medicare to negotiate prices, as it now can for a small number of high-cost drugs under recent legislation, is a step toward aligning U.S. prices with those in other wealthy countries, where central negotiation keeps costs far lower. Expanding that power to cover more drugs, and sooner after they hit the market, would give the government real leverage to push back on launch prices that now routinely exceed $100,000 a year.

The second is patent reform. Today, a single drug is rarely protected by a single patent. Instead, companies build what are often called patent thickets — dozens or even hundreds of overlapping patents on minor tweaks to formulation, dosing, or delivery devices that can extend a monopoly for years or decades after the original patent should have expired. Alongside other tactics like pay-for-delay deals, where brand-name makers pay generics to stay off the market, this keeps cheaper alternatives out of reach. Reform would mean limiting patents to truly new inventions, tightening the standard for what counts as patentable, cracking down on anti-competitive settlements, and making it easier for the Patent Office and the FDA to challenge weak or duplicative patents.

Together, these changes would not stifle innovation. Most breakthrough research already comes from publicly funded labs and universities, with private companies stepping in later to bring drugs to market. What reform would do is restore the original bargain of the patent system: a limited period of exclusivity in exchange for a genuine invention, followed by open competition that brings prices down for everyone.

We hope this article has given you a clearer understanding of how drug pricing works and why so many life-saving medications come with such a high price tag. From taxpayer-funded research to patent protections and market exclusivity, the journey of a drug from the lab to your pharmacy involves far more than just development costs. By staying informed, exploring generic alternatives, and supporting greater transparency in the pharmaceutical industry, you can better navigate these costs and advocate for a more affordable healthcare system for everyone.

——————————